Trusted by generations of healthcare providers, PDR.net supports prescribing decisions and patient adherence to improve health. PDR delivers critical drug information and resources trusted and relied on by prescribers for generations.

2022年6月2日 · Among all cytokines, Growth and Differentiation Factor-15 (GDF-15) was found significantly over-expressed in serum of EHE pts (n = 23), particularly those with the most aggressive clinical variant, compared to healthy subjects (n = 23; p< 0.01). Consistently, EHE PDX and cell culture were found to release in the blood/culture medium GDF-15.

Epithelioid hemangioendothelioma, or EHE, is a rare cancer that grows from the cells that make up the blood vessels. This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone. It usually happens in people between 30 and 50 years of age but can also occur in young children and older people.

Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement.

2021年7月21日 · MSK researchers are developing new guidelines to treat a rare sarcoma, EHE. Caring for sarcoma patients, who are typically young, requires experts from many disciplines and the MSK Adolescent and Young Adult Program. Learning more about epithelioid hemangioendothelioma (EHE) is an ongoing mission of MSK’s sarcoma research.

Written by a global team of epithelioid hemangioendothelioma (EHE) experts, this important resource provides guidance for the treatment and management of EHE.

2018年3月15日 · Epithelioid hemangioendothelioma (EHE) is a rare malignant vascular tumor that develops from vascular endothelial or pre-endothelial cells [1]. It was initially described in 1975 by Dail and Liebow as a bronchoalveolar cell carcinoma of the lung.

In this international, observational retrospective effort, we collected all the cases of histologically proven, advanced EHE, diagnosed from 2000 onwards and treated with systemic therapies at the major sarcoma reference centres within the framework of the World Sarcoma Network, with the aim of studying their potential.

Background: EHE is an ultra-rare sarcoma marked by two specificfusions, WWTR1-CAMTA1 (~90%) and YAP1-TFE3 (~10%). The clinical course of EHE ranges from indolent to highly aggressive, often associated with systemic paraneoplastic symptoms. Molecular predictors of clinical outcome are un-known.

上皮样血管内皮瘤 (ehe) 是一种极为罕见的易位血管肉瘤。ehe 的临床行为是多变的，从低级别恶性肿瘤到高级别肉瘤，其特点是全身受累倾向高。目前没有专门针对 ehe 批准的活性全身性药物，这通常对肉瘤中使用的抗肿瘤药物具有耐药性。